Responses
Infectious diseases
Protocol
Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo
Compose a Response to This Article
Other responses
No responses have been published for this article.